Editorial

Published on 23 May 2024

Editorial: Novel therapeutic targets of gastric carcinogenesis: from basic research to drug development and clinical application

in Cancer Molecular Targets and Therapeutics

Chenchen Niu
Dong Ren
Bella Lingjia Liu

Frontiers in Oncology

doi 10.3389/fonc.2024.1431520

470 views

Mini Review

Published on 22 May 2024

Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance

in Cancer Molecular Targets and Therapeutics

Jameela Lokhandwala
Tracess B. Smalley
Timothy H. Tran

Frontiers in Oncology

doi 10.3389/fonc.2024.1394702

3,138 views
3 citations

Original Research

Published on 17 May 2024

The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy

in Cancer Molecular Targets and Therapeutics

Priya U. Kumthekar
Barbara Blouw
Perry Corkos
Seema Nagpal
Arushi Tripathy
David Piccioni
Michael Youssef

Frontiers in Oncology

doi 10.3389/fonc.2024.1402651

957 views
2 citations

Systematic Review

Published on 16 May 2024

Evolution and impact of molecular glue research: a bibliometric analysis from 2000 to 2023

in Cancer Molecular Targets and Therapeutics

Dian Li
Jingyi Cheng
Zhigen Yuan
Kexin Deng

Frontiers in Oncology

doi 10.3389/fonc.2024.1401257

1,630 views

Retraction

Published on 14 May 2024

Retraction: Exosomes derived from microRNA-148b-3p-overexpressing human umbilical cord mesenchymal stem cells restrain breast cancer progression

in Cancer Molecular Targets and Therapeutics

Frontiers Editorial Office

Frontiers in Oncology

doi 10.3389/fonc.2024.1422567

645 views

Original Research

Published on 14 May 2024

Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis

in Cancer Molecular Targets and Therapeutics

Mengzhang Xie
Qi Huang
Taojun Gong
Yitian Wang
Zhuangzhuang Li
Minxun Lu
Yi Luo
Li Min
Yong Zhou
Chongqi Tu

Frontiers in Oncology

doi 10.3389/fonc.2024.1399574

1,091 views
1 citation

Original Research

Published on 13 May 2024

Chloroquine-induced DNA damage synergizes with DNA repair inhibitors causing cancer cell death

in Cancer Molecular Targets and Therapeutics

Diego Iglesias-Corral
Paula García-Valles
Nuria Arroyo-Garrapucho
Elena Bueno-Martínez
Juan Manuel Ruiz-Robles
María Ovejero-Sánchez
Rogelio González-Sarmiento
Ana Belén Herrero

Frontiers in Oncology

doi 10.3389/fonc.2024.1390518

1,754 views
1 citation

Review

Published on 10 May 2024

Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment

in Cancer Molecular Targets and Therapeutics

Szu-Aun Long
Amber M. Amparo
Grace Goodhart
Syed A. Ahmad
Andrew M. Waters

Frontiers in Oncology

doi 10.3389/fonc.2024.1402128

4,464 views
1 citation

Review

Published on 10 May 2024

The intricate interplay between cancer stem cells and cell-of-origin of cancer: implications for therapeutic strategies

in Cancer Molecular Targets and Therapeutics

Oluwaseun Adebayo Bamodu
Chen-Chih Chung
Thomas R. Pisanic
Alexander T. H. Wu

Frontiers in Oncology

doi 10.3389/fonc.2024.1404628

1,191 views

Review

Published on 08 May 2024

Current status, challenges and prospects of antifouling materials for oncology applications

in Cancer Molecular Targets and Therapeutics

Yingfeng Zhang
Congcong Sun

Frontiers in Oncology

doi 10.3389/fonc.2024.1391293

1,619 views
2 citations

Review

Published on 08 May 2024

The use of photodynamic therapy in medical practice

in Cancer Molecular Targets and Therapeutics

David Aebisher
Kacper Rogóż
Angelika Myśliwiec
Klaudia Dynarowicz
Rafał Wiench
Grzegorz Cieślar
Aleksandra Kawczyk-Krupka
Dorota Bartusik-Aebisher

Frontiers in Oncology

doi 10.3389/fonc.2024.1373263

2,987 views
5 citations

Review

Published on 02 May 2024

KRAS G12C inhibitor combination therapies: current evidence and challenge

in Cancer Molecular Targets and Therapeutics

Hirotaka Miyashita
Shumei Kato
David S. Hong

Frontiers in Oncology

doi 10.3389/fonc.2024.1380584

7,290 views
6 citations

Mini Review

Published on 02 May 2024

Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer

in Cancer Molecular Targets and Therapeutics

Caroline Linde
Yu-Ting Chien
Zhiqian Chen
Qingxin Mu

Frontiers in Oncology

doi 10.3389/fonc.2024.1393492

1,683 views

Correction

Published on 01 May 2024

Corrigendum: The role of microtubules in pancreatic cancer: therapeutic progress

in Cancer Molecular Targets and Therapeutics

Mugahed Abdullah Hasan Albahde
Bulat Abdrakhimov
Guo-Qi Li
Xiaohu Zhou
Dongkai Zhou
Hao Xu
Huixiao Qian
Weilin Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1414456

545 views

Original Research

Published on 30 Apr 2024

MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-epsilon

in Cancer Molecular Targets and Therapeutics

Jitender Monga
Ritisha Ghosh
Rohith Guddeti
Dhananjay Chitale
Gazala Khan
Jagadananda Ghosh

Frontiers in Oncology

doi 10.3389/fonc.2024.1387535

1,156 views

Review

Published on 25 Apr 2024

Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression

in Cancer Molecular Targets and Therapeutics

Xia Lei
Ya Ni Gou
Jin Yong Hao
Xiao Jun Huang

Frontiers in Oncology

doi 10.3389/fonc.2024.1375729

2,186 views
1 citation

Navigation group

Articles

Editorial: Novel therapeutic targets of gastric carcinogenesis: from basic research to drug development and clinical application

Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance

The HER2 flip-HER2 amplification of tumor cells in the cerebrospinal fluid of breast cancer patients with leptomeningeal disease: implications for treating the LM tumor with anti-HER2 therapy

Evolution and impact of molecular glue research: a bibliometric analysis from 2000 to 2023

Retraction: Exosomes derived from microRNA-148b-3p-overexpressing human umbilical cord mesenchymal stem cells restrain breast cancer progression

Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis

Chloroquine-induced DNA damage synergizes with DNA repair inhibitors causing cancer cell death

Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment

The intricate interplay between cancer stem cells and cell-of-origin of cancer: implications for therapeutic strategies

Current status, challenges and prospects of antifouling materials for oncology applications

The use of photodynamic therapy in medical practice

KRAS G12C inhibitor combination therapies: current evidence and challenge

Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer

Corrigendum: The role of microtubules in pancreatic cancer: therapeutic progress

MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-epsilon

Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression